| Date Filed | Type | Description |
| 08/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/24/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 07/17/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
4
| Harwin Peter Evan (Director) has filed a Form 4 on Viridian Therapeutics, Inc.\DE|
Txns:
| Granted 20,000 options to buy
@ $27.67, valued at
$553.4k
|
|
| 06/16/2023 |
4
| Moses Jennifer K. (Director) has filed a Form 4 on Viridian Therapeutics, Inc.\DE|
Txns:
| Granted 20,000 options to buy
@ $27.67, valued at
$553.4k
|
|
| 06/16/2023 |
4
| Kiselak Tomas (Director) has filed a Form 4 on Viridian Therapeutics, Inc.\DE|
Txns:
| Granted 20,000 options to buy
@ $27.67, valued at
$553.4k
|
|
| 06/16/2023 |
4
| Morris Arlene (Director) has filed a Form 4 on Viridian Therapeutics, Inc.\DE|
Txns:
| Granted 20,000 options to buy
@ $27.67, valued at
$553.4k
|
|
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/06/2023 |
4
| Meisner Lara (Chief Legal Officer) has filed a Form 4 on Viridian Therapeutics, Inc.\DE|
Txns:
| Sold 1,875 shares
@ $24.21, valued at
$45.4k
Sold 499 shares
@ $25.03, valued at
$12.5k
Sold 5,126 shares
@ $25.02, valued at
$128.3k
Exercised 1,875 options to buy
@ $14, valued at
$26.3k
Exercised 499 options to buy
@ $18.51, valued at
$9.2k
Exercised 5,126 options to buy
@ $18.51, valued at
$94.9k
|
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
SC 13G
| Paradigm Biocapital Advisors LP reports a 5.4% stake in Viridian Therapeutics, Inc. |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
4
| Myers Scott Dunseth (CEO) has filed a Form 4 on Viridian Therapeutics, Inc.\DE|
Txns:
| Bought 5,500 shares
@ $29.1499, valued at
$160.3k
|
|
| 03/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/10/2023 |
4
| Meisner Lara (General Counsel and Secretary) has filed a Form 4 on Viridian Therapeutics, Inc.\DE|
Txns:
| Sold 29,971 shares
@ $29.07, valued at
$871.3k
|
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/08/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 4.7% stake in Viridian Therapeutics Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 2.7% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| TCG Crossover GP I, LLC reports a 2.4% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.6% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.2% stake in Viridian Therapeutics Inc. |
|